Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Changes in Methylation and Chromatin Accessibility Underlie Subtype Classification and Disease Evolution in Waldenström's Macroglobulinemia

Zachary R Hunter, Nickolas Tsakmaklis, Kris Richardson, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Shirong Liu, Catherine A. Flynn, Kirsten Meid, Christopher J Patterson, Mariateresa Fulciniti, Mehmet K. Samur, Kenneth C. Anderson, Nikhil C Munshi, Shayna R Sarosiek, Jorge J. Castillo, Ari M Melnick, Steven P Treon

Blood (2023) 142 (Supplement 1): 755.

https://doi.org/10.1182/blood-2023-190825

Published: 2023

Journal Articles

Pacritinib Blocks Key Pro-Survival Signaling Related to Mutated MYD88, Produces High Levels of Apoptosis and Overcomes Mutated BTK Cys481 Related BTK-Inhibitor Resistance

Shirong Liu, Amanda Kofides, Xia Liu, Alexa G Canning, Nickolas Tsakmaklis, Maria Luisa Guerrera, Christopher J Patterson, Zachary R Hunter, Kris Richardson, Catherine A. Flynn, Kirsten Meid, Megan Little, Katherine Stockman, Timothy P. White, Shayna R Sarosiek, Jorge J. Castillo, Steven P Treon

Blood (2023) 142 (Supplement 1): 3300.

https://doi.org/10.1182/blood-2023-190463

Published: 2023

Journal Articles

Aberrant Expression of Spliced WNK2 Is an Early Event in MYD88 Mutated WM That Activates ERK1/2 and Supports Tumor Growth

Maria Luisa Guerrera, Zachary R Hunter, Kris Richardson, Nickolas Tsakmaklis, Amanda Kofides, Shirong Liu, Christopher J Patterson, Eugenio Morelli, Jorge J. Castillo, Shayna R Sarosiek, Catherine A. Flynn, Kirsten Meid, Andrew R. Branagan, Ruben D. Carrasco, Kenneth C. Anderson, Nikhil C Munshi, Steven P Treon, Xia Liu

Blood (2023) 142 (Supplement 1): 3303.

https://doi.org/10.1182/blood-2023-190880

Published: 2023

Journal Articles

Novel Isoforms Identified By Isoseq Analysis Drive Expression Differences in Key Genes That Delineate the Subtypes of Waldenstrom's Macroglobulinemia

Kris Richardson, Nickolas Tsakmaklis, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Shirong Liu, Catherine A. Flynn, Kirsten Meid, Christopher J Patterson, Mariateresa Fulciniti, Mehmet K. Samur, Kenneth C. Anderson, Nikhil C Munshi, Shayna R Sarosiek, Jorge J. Castillo, Zachary R Hunter, Steven P Treon

Blood (2023) 142 (Supplement 1): 1946.

https://doi.org/10.1182/blood-2023-190631

Published: 2023

Journal Articles

Novel Protacs Demonstrate Dual Kinase Inhibition and Degradation of HCK and BTK, and Are Highly Active in MYD88 Mutated WM and ABC DLBCL Cells

Shirong Liu, John M Hatcher, Amanda Kofides, Alexa G Canning, Jinhua Wang, Xia Liu, Nickolas Tsakmaklis, Maria Luisa Guerrera, Christopher J Patterson, Zachary R Hunter, Shayna R Sarosiek, Jorge J. Castillo, Sara J. Buhrlage, Steven P Treon

Blood (2023) 142 (Supplement 1): 3298.

https://doi.org/10.1182/blood-2023-190369

Published: 2023

Journal Articles

Quantitative MYD88 L265P Analysis Represents a Powerful Tool for Assessing Disease Response and Evaluating Clinical Trial Performance in Waldenstrom's Macroglobulinemia

Nickolas Tsakmaklis, Zachary R Hunter, Xia Liu, Amanda Kofides, Shirong Liu, Alexa G Canning, Kris Richardson, Maria Luisa Guerrera, Christopher J Patterson, Kirsten Meid, Timothy P. White, Megan Little, Katherine Stockman, Joshua Gustine, Catherine A. Flynn, Andrew R. Branagan, Shayna R Sarosiek, Jorge J. Castillo, Steven P Treon

Blood (2023) 142 (Supplement 1): 211.

https://doi.org/10.1182/blood-2023-190520

Published: 2023

Journal Articles

Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia

Jorge J. Castillo, Shayna R Sarosiek, Andrew R. Branagan, Catherine A. Flynn, Megan Little, Katherine Stockman, Timothy P. White, Alexandra N. Eurell, Maria Luisa Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Kris Richardson, Nickolas Tsakmaklis, Kirsten Meid, Christopher J Patterson, Zachary R Hunter, Steven P Treon

Blood (2023) 142 (Supplement 1): 1661.

https://doi.org/10.1182/blood-2023-174375

Published: 2023

Journal Articles

Early Subclones Showing Aberrant Co-Expression of Stem Cell, T Cell and Myeloid Genes Can be Detected By Flow Cytometry in MYD88 Mutated Waldenström's Macroglobulinemia Patients

Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Nickolas Tsakmaklis, Kris Richardson, Shirong Liu, Christopher J Patterson, Catherine A. Flynn, Kirsten Meid, Nikhil C Munshi, Kenneth C. Anderson, Shayna R Sarosiek, Jorge J. Castillo, Steven P Treon, Zachary R Hunter

Blood (2023) 142 (Supplement 1): 1952.

https://doi.org/10.1182/blood-2023-190942

Published: 2023

Journal Articles

Atypical Stem Cell, Pre-B-Cell, T-Cell and Myeloid Gene Expression Characterizes Early Waldenstrom's Macroglobulinemia Clones Which Diminishes with Advancing Disease and Has Therapeutic Implications

Blood (2023) 142 (Supplement 1): 756.

https://doi.org/10.1182/blood-2023-190685

Published: 2023

Journal Articles

Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

Blood (2022) 140 (Supplement 1): 10094–10096.

https://doi.org/10.1182/blood-2022-167899

Published: 2022

Journal Articles

The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia

Blood (2022) 140 (Supplement 1): 1549–1550.

https://doi.org/10.1182/blood-2022-169863

Published: 2022

Journal Articles

Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia

Jorge J. Castillo, Shayna Sarosiek, Andrew R. Branagan, David J. Sermer, Catherine A. Flynn, Carly Leventoff, Megan Little, Timothy P White, Kirsten Meid, Alexa Canning, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Christopher J Patterson, Zachary R Hunter, Steven P Treon

Blood (2022) 140 (Supplement 1): 564–565.

https://doi.org/10.1182/blood-2022-155610

Published: 2022

Journal Articles

Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom's Macroglobulinemia

Blood (2022) 140 (Supplement 1): 3541–3542.

https://doi.org/10.1182/blood-2022-170254

Published: 2022

Journal Articles

Multi-Omic Analysis of 253 Untreated Patients with Waldenström's Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression

Blood (2022) 140 (Supplement 1): 1740–1741.

https://doi.org/10.1182/blood-2022-170412

Published: 2022

Journal Articles

The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTK Cys481 ibrutinib resistance

Blood (2021) 138 (20): 1966–1979.

https://doi.org/10.1182/blood.2021011405

Published: 2021

Includes: Supplemental data

Journal Articles

Pirtobrutinib (LOXO-305) Is Active and Overcomes ERK Related Pro-Survival Signaling in Ibrutinib Resistant, BTK Cys481 Mutant Expressing WM and ABC DLBCL Lymphoma Cells Driven By Activating MYD88 Mutations

Manit Munshi, Xia Liu, Amanda Kofides, Nickolas Tsakmaklis, Joshua Gustine, Shayna Sarosiek, Catherine A Flynn, Kirsten Meid, Timothy P White, Carly Leventoff, Christopher J Patterson, Andrew R. Branagan, Prafulla Gokhale, Michael J Poitras, Zachary R Hunter, Maria Luisa Guerrera, Jorge J. Castillo, Guang Yang, Steven P Treon

Blood (2021) 138 (Supplement 1): 2261.

https://doi.org/10.1182/blood-2021-153856

Published: 2021

Journal Articles

COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

Blood (2021) 138 (Supplement 1): 3801.

https://doi.org/10.1182/blood-2021-154089

Published: 2021

Journal Articles

A New Role for the SRC Family Member HCK As a Driver of BCR/SYK Signaling in MYD88 Mutated Lymphomas

Blood (2021) 138 (Supplement 1): 3512.

https://doi.org/10.1182/blood-2021-153610

Published: 2021

Journal Articles

The ERK1/2 Regulator WNK2 Shows Differential Expression and Isoform Usage, Primarily Driven By Aberrant Methylation, in MYD88 Mutated Waldenström's Macroglobulinemia

Maria Luisa Guerrera, Guang Yang, Xia Liu, Nickolas Tsakmaklis, Maria G Demos, Amanda Kofides, Manit Munshi, Lian Xu, Christopher J Patterson, Jorge J. Castillo, Shayna Sarosiek, Catherine A Flynn, Kirsten Meid, Joshua Gustine, Tomasz Sewastianik, Ruben D. Carrasco, Steven P Treon, Zachary R Hunter

Blood (2021) 138 (Supplement 1): 2692.

https://doi.org/10.1182/blood-2021-154160

Published: 2021

Journal Articles

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia

Blood (2021) 138 (17): 1535–1539.

https://doi.org/10.1182/blood.2021012953

Published: 2021

Includes: Supplemental data

NARROW

Changes in Methylation and Chromatin Accessibility Underlie Subtype Classification and Disease Evolution in Waldenström's Macroglobulinemia

Pacritinib Blocks Key Pro-Survival Signaling Related to Mutated MYD88, Produces High Levels of Apoptosis and Overcomes Mutated BTK Cys481 Related BTK-Inhibitor Resistance

Aberrant Expression of Spliced WNK2 Is an Early Event in MYD88 Mutated WM That Activates ERK1/2 and Supports Tumor Growth

Novel Isoforms Identified By Isoseq Analysis Drive Expression Differences in Key Genes That Delineate the Subtypes of Waldenstrom's Macroglobulinemia

Novel Protacs Demonstrate Dual Kinase Inhibition and Degradation of HCK and BTK, and Are Highly Active in MYD88 Mutated WM and ABC DLBCL Cells

Quantitative MYD88 L265P Analysis Represents a Powerful Tool for Assessing Disease Response and Evaluating Clinical Trial Performance in Waldenstrom's Macroglobulinemia

Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia

Early Subclones Showing Aberrant Co-Expression of Stem Cell, T Cell and Myeloid Genes Can be Detected By Flow Cytometry in MYD88 Mutated Waldenström's Macroglobulinemia Patients

Atypical Stem Cell, Pre-B-Cell, T-Cell and Myeloid Gene Expression Characterizes Early Waldenstrom's Macroglobulinemia Clones Which Diminishes with Advancing Disease and Has Therapeutic Implications

Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia

Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia

Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom's Macroglobulinemia

Multi-Omic Analysis of 253 Untreated Patients with Waldenström's Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression

The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTK Cys481 ibrutinib resistance

Pirtobrutinib (LOXO-305) Is Active and Overcomes ERK Related Pro-Survival Signaling in Ibrutinib Resistant, BTK Cys481 Mutant Expressing WM and ABC DLBCL Lymphoma Cells Driven By Activating MYD88 Mutations

COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

A New Role for the SRC Family Member HCK As a Driver of BCR/SYK Signaling in MYD88 Mutated Lymphomas

The ERK1/2 Regulator WNK2 Shows Differential Expression and Isoform Usage, Primarily Driven By Aberrant Methylation, in MYD88 Mutated Waldenström's Macroglobulinemia

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only